¼¼°èÀÇ ¹ÙÀÌ¿À¼ÒÀç ½ÃÀå
Biomaterials
»óǰÄÚµå : 1768215
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 134 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,171,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,515,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹ÙÀÌ¿À¼ÒÀç ¼¼°è ½ÃÀåÀº 2030³â±îÁö 2,156¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1,135¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹ÙÀÌ¿À¼ÒÀç ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 11.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 2,156¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¸ÞÅ»¸¯ ºÐ¾ß´Â CAGR 11.3%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1,191¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Æú¸®¸Ó ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 12.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 291¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 15.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹ÙÀÌ¿À¼ÒÀç ½ÃÀåÀº 2024³â¿¡ 291¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 514¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 15.0%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 7.4%¿Í 9.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 8.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ¹ÙÀÌ¿À¼ÒÀç ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

¹ÙÀÌ¿À¼ÒÀç ½ÃÀåÀÇ Çõ½Å ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

»ýüÀç·á´Â »ýü ½Ã½ºÅÛ°ú »óÈ£ ÀÛ¿ëÇϵµ·Ï ¼³°èµÈ ¹°ÁúÀÇ ÀÏÁ¾À¸·Î ÀÇ·á, Á¦¾à, ±â¼ú Çõ½ÅÀÇ ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù. »óó Ä¡À¯¿Í ¾à¹°Àü´Þ¿¡¼­ Àΰø Àå±â¿Í Àΰø º¸Ã¶¹°¿¡ À̸£±â±îÁö ¹ÙÀÌ¿À¼ÒÀç´Â ÇコÄɾ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. »ýºÐÇØ¼º °íºÐÀÚ, »ýüȰ¼º ¼¼¶ó¹Í, ³ª³ë ¼ÒÀç µî ÷´Ü ¹ÙÀÌ¿À¼ÒÀçÀÇ °³¹ßÀº ÀÇ·á±â±âÀÇ ¼³°è, Á¦Á¶ ¹× ÀÎü¿ÍÀÇ ÅëÇÕ ¹æ½ÄÀ» Å©°Ô º¯È­½Ã۰í ÀÖ½À´Ï´Ù. Àç·á°úÇаú »ý¸í°øÇÐÀÇ ¸¸³²Àº »ýüÀûÇÕ¼º»Ó¸¸ ¾Æ´Ï¶ó Á¶Á÷ Àç»ýÀ» ÃËÁøÇÏ°í ¼¼Æ÷ÀÇ ¼ºÀåÀ» Áö¿øÇÏ´Â Àç·á¸¦ ¸¸µé¾î³»°í ÀÖÀ¸¸ç, 3D ÇÁ¸°ÆÃ°ú °°Àº »õ·Î¿î ±â¼úÀº Çõ½ÅÀ» ´õ¿í ÃËÁøÇÏ¿© Àü·Ê ¾ø´Â Á¤¹Ðµµ¿Í ±â´É¼ºÀ» °®Ãá ¸ÂÃãÇü ÀÓÇöõÆ® ¹× º¸Ã¶¹° Á¦ÀÛÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÓÇöõÆ® ¹× º¸Ã¶¹° Á¦ÀÛÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿Í Àç»ý Ä¡·á·ÎÀÇ Àüȯ¿¡ µû¶ó ¹ÙÀÌ¿À¼ÒÀç´Â ȯÀÚ °á°ú¸¦ °³¼±Çϰí ÀÇ·á °³ÀÔÀÇ ¿ª·®À» È®ÀåÇÒ ¼ö ÀÖ´Â ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ¹Ì·¡ ÀÇ·áÀÇ ÇÙ½É ¿ä¼Ò·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ÃÖÁ¾ ¿ëµµ´Â ¹ÙÀÌ¿À¼ÒÀçÀÇ ¹Ì·¡¸¦ ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

¹ÙÀÌ¿À¼ÒÀç´Â ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ Æø³Ð°Ô »ç¿ëµÇ°í ÀÖÁö¸¸, ±× Áß¿¡¼­µµ ÇコÄÉ¾î ºÐ¾ß°¡ ¼ö¿äÀÇ Áß½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. Á¤Çü¿Ü°ú¿¡¼­ ¹ÙÀÌ¿À¼ÒÀç´Â Àΰø°üÀý, »À À̽Ä, ôÃß ÀÓÇöõÆ® µî¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, ƼŸ´½°ú »ýüÈí¼ö¼º Æú¸®¸Ó¿Í °°Àº ¼ÒÀç°¡ »ÀÀÇ Ä¡À¯¿Í Àç»ýÀ» µ½½À´Ï´Ù. °­µµ¿Í »ýüÀûÇÕ¼ºÀÌ ¸ðµÎ ¿ä±¸µÇ´Â Ä¡°ú¿ë ÀÓÇöõÆ®¿¡¼­´Â Áö¸£ÄڴϾƳª º¹ÇÕ·¹Áø°ú °°Àº ÷´Ü ¹ÙÀÌ¿À¼ÒÀç¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Á¤Çü¿Ü°ú¿Í Ä¡°ú»Ó¸¸ ¾Æ´Ï¶ó, ¹ÙÀÌ¿À¼ÒÀç´Â ½ÉÇ÷°ü ÀÇ·á ºÐ¾ß¿¡¼­µµ Å« ÁøÀüÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ½ºÅÙÆ®, ½ÉÀåÆÇ¸·, Àΰø Ç÷°üÀº Ç÷ÀüÁõÀÇ À§ÇèÀ» ÁÙÀ̰í ÀÓÇöõÆ® ¼ö¸íÀ» Çâ»ó½ÃŰ´Â »ýüȰ¼º ¹°Áú·Î Á¦Á¶µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¶Á÷°øÇаú »óó Ä¡·á´Â »ýüÀç·á°¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â µÎ °¡Áö ¼ºÀå ºÐ¾ß·Î, ¼¼Æ÷ ¹ÝÀÀÀ» Çâ»ó½Ã۰í Ä¡À¯¸¦ °¡¼ÓÈ­Çϸç ÈäÅÍ Çü¼ºÀ» ¾ïÁ¦ÇÏ´Â »õ·Î¿î Àç·á°¡ ¼³°èµÇ°í ÀÖ½À´Ï´Ù. ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡¼­µµ »ýüÈí¼ö¼º ¹× »ýüÀûÇÕ¼º Àç·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Àç·á´Â Ä¡·áÁ¦ÀÇ ¹æÃâ°ú Ç¥ÀûÀ» Á¦¾îÇÏ¿© ´õ ³ôÀº È¿´É°ú ºÎÀÛ¿ëÀ» ÁÙÀÏ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

¹ÙÀÌ¿À¼ÒÀçÀÇ ´É·Â Çâ»ó¿¡ ÀÖ¾î ±â¼úÀÇ ¿ªÇÒÀº ¹«¾ùÀΰ¡?

±â¼úÀÇ ¹ßÀüÀº ƯÈ÷ ³ª³ë±â¼ú, »ý¸í°øÇÐ, ½º¸¶Æ® Àç·áÀÇ »ç¿ëÀ» ÅëÇØ ¹ÙÀÌ¿À¼ÒÀç ½ÃÀåÀ» »õ·Î¿î ¿µ¿ªÀ¸·Î ²ø¾î¿Ã¸®°í ÀÖ½À´Ï´Ù. ³ª³ë±â¼úÀº ¼¼Æ÷ ¼öÁØ¿¡¼­ »ýü Á¶Á÷°ú »óÈ£ ÀÛ¿ëÇÒ ¼ö ÀÖ´Â ³ª³ë½ºÄÉÀÏ ¹ÙÀÌ¿À¼ÒÀçÀÇ ¹®À» ¿­¾î ü³» ÅëÇÕ°ú ¼º´ÉÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ª³ë¹°ÁúÀº ¾à¹°Àü´Þ°ú °°Àº ºÐ¾ß¿¡¼­ °ÔÀÓ Ã¼ÀÎÀú°¡ µÉ ¼ö ÀÖÀ½À» Áõ¸íÇϰí ÀÖ½À´Ï´Ù. ³ª³ëÀÔÀڴ ƯÁ¤ ¼¼Æ÷³ª Á¶Á÷À» Ç¥ÀûÀ¸·Î ÇÏ¿© ¾à¹°À» º¸´Ù È¿À²ÀûÀ¸·Î Àü´ÞÇϰí Àü½Å ºÎÀÛ¿ëÀ» ÁÙÀÏ ¼ö ÀÖµµ·Ï ¼³°èÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î, 3D ÇÁ¸°ÆÃÀº ÀÇ·á ºÐ¾ß¿¡¼­ »ýü Àç·áÀÇ »ç¿ë ¹æ½Ä¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ °³º° ȯÀÚÀÇ ÇØºÎÇÐÀû ±¸Á¶¿¡ ¸Â°Ô °íµµ·Î ¸ÂÃãÈ­µÈ ÀÓÇöõÆ®, º¸Ã¶¹°, ½ÉÁö¾î Àå±âÀÇ ¹ßÆÇ±îÁö Á¦ÀÛÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. »ý¸í°øÇÐÀº »ýüÀç·áÀÇ ´É·ÂÀ» ´õ¿í Çâ»ó½Ã۰í ÀÖÀ¸¸ç, À¯Àü°øÇÐ ¹× Á¶Á÷ ½ºÄ³ÆúµùÀÇ Çõ½ÅÀº ÇÕ¼º°ú »ý¹°ÇÐÀû ¼ººÐÀ» À¶ÇÕÇÑ ¹ÙÀÌ¿ÀÇÏÀ̺긮µå Àç·áÀÇ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½º¸¶Æ® ¹ÙÀÌ¿À¼ÒÀç´Â pH, ¿Âµµ, È­ÇÐÀû ½ÅÈ£¿Í °°Àº ü³» º¯È­¿¡ ÀûÀÀÇÒ ¼ö ÀÖÀ¸¸ç, ¿ªµ¿ÀûÀÎ »ý¹°ÇÐÀû ȯ°æ¿¡¼­ ³ôÀº È¿°ú¸¦ ¹ßÈÖÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¹ÙÀÌ¿À¼ÒÀçÀÇ ¼º´ÉÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó, ÀÌÀü¿¡´Â ºÒ°¡´ÉÇÏ´Ù°í ¿©°ÜÁ³´ø ºÐ¾ß·ÎÀÇ Àû¿ëÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À¼ÒÀç ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

»ýüÀç·á ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ÀÇ·á ¿ëµµÀÇ È®´ë, ¼ÒºñÀÚ ±â´ëÄ¡ÀÇ º¯È­ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿øµ¿·Â Áß Çϳª´Â °ñ°üÀý¿°, ½ÉÇ÷°üÁúȯ, ´ç´¢º´°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡À̸ç, ÀÌ·¯ÇÑ Áúȯ¿¡´Â ÷´Ü »ýüÀç·á ±â¹Ý ÀÓÇöõÆ®, º¸Ã¶¹°, ¾à¹°Àü´Þ ½Ã½ºÅÛÀÌ ÇÊ¿äÇÕ´Ï´Ù. ³ëÀεéÀº Á¤Çü¿Ü°ú¿ë ÀÓÇöõÆ®, Ä¡°ú¿ë ¼öº¹¹°, ½ÉÇ÷°ü ÀåÄ¡¸¦ ÇÊ¿ä·Î ÇÒ °¡´É¼ºÀÌ ³ôÀ¸¸ç, ÀÌ´Â ¸ðµÎ ÷´Ü »ýüÀç·á¿¡ ÀÇÁ¸Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, ÃÖ¼Òħ½ÀÀû ½Ã¼ú°ú ȸº¹ ½Ã°£ ´ÜÃà¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ¿ä±¸´Â ½Åü¿ÍÀÇ ´õ ³ªÀº ÅëÇÕÀ» ÃËÁøÇϰí Ä¡À¯ °úÁ¤À» °­È­ÇÏ´Â »ýü Àç·áÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ³ª³ë±â¼ú, Á¶Á÷°øÇÐ, 3D ÇÁ¸°ÆÃ°ú °°Àº ±â¼ú ¹ßÀüÀº ¿ì¼öÇÑ ¼º´É°ú ¸ÂÃãÇüÀ» Á¦°øÇÏ´Â Â÷¼¼´ë »ýüÀç·áÀÇ Åº»ýÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ÀÇ·á ¹× ÇコÄɾî¿ë ¹ÙÀÌ¿À¼ÒÀç ¿¬±¸°³¹ß¿¡ ´ëÇÑ ±ÔÁ¦ Áö¿ø°ú Á¤ºÎÀÇ ÀçÁ¤Àû Áö¿øÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü ¼¼°èÀûÀ¸·Î ÀÇ·á ½Ã½ºÅÛÀÌ ¸ÂÃãÇü ÀÇ·á ¹× Àç»ý Ä¡·á·Î ÀüȯµÊ¿¡ µû¶ó ȯÀÚ °³°³ÀÎÀÇ ¿ä±¸¿¡ ¸Â´Â ¹ÙÀÌ¿À ¿£Áö´Ï¾î¸µ ¼ÒÀç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ¹ÙÀÌ¿À¼ÒÀç ºÐ¾ßÀÇ Çõ½Å°ú ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(±Ý¼Ó, Æú¸®¸Ó, ¼¼¶ó¹Í, õ¿¬¹°), ¿ëµµ(Á¤Çü¿Ü°ú, ½ÉÇ÷°ü, ¾à¹°Àü´Þ ½Ã½ºÅÛ, Ä¡°ú, ½Å°æÁúȯ, ¾È°ú, ¼ºÇü¿Ü°ú, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå°ú °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Biomaterials Market to Reach US$215.6 Billion by 2030

The global market for Biomaterials estimated at US$113.5 Billion in the year 2024, is expected to reach US$215.6 Billion by 2030, growing at a CAGR of 11.3% over the analysis period 2024-2030. Metallic, one of the segments analyzed in the report, is expected to record a 11.3% CAGR and reach US$119.1 Billion by the end of the analysis period. Growth in the Polymeric segment is estimated at 12.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$29.1 Billion While China is Forecast to Grow at 15.0% CAGR

The Biomaterials market in the U.S. is estimated at US$29.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$51.4 Billion by the year 2030 trailing a CAGR of 15.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.4% and 9.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Biomaterials Market - Key Trends & Drivers Summarized

What is Driving Innovation in the Biomaterials Market?

Biomaterials, a class of substances engineered to interact with biological systems, are at the forefront of medical, pharmaceutical, and technological innovations. From wound healing and drug delivery to artificial organs and prosthetics, biomaterials have revolutionized healthcare. The development of advanced biomaterials, such as biodegradable polymers, bioactive ceramics, and nanomaterials, is transforming how medical devices are designed, produced, and integrated with the human body. The intersection of material science with biotechnology has led to the creation of materials that can not only be biocompatible but also promote tissue regeneration and support cell growth. Emerging technologies such as 3D printing are further propelling innovation, allowing the creation of customized implants and prosthetics with unprecedented precision and functionality. The global shift towards personalized medicine and regenerative therapies has positioned biomaterials as a critical component in the future of healthcare, offering solutions that improve patient outcomes and extend the capabilities of medical interventions.

How Are End-Use Applications Shaping the Future of Biomaterials?

Biomaterials are finding a wide range of applications across various sectors, with healthcare being the primary driver of demand. In orthopedics, biomaterials are widely used in joint replacements, bone grafts, and spinal implants, where materials such as titanium and bioresorbable polymers support bone healing and regeneration. Dental implants, which require both strength and biocompatibility, increasingly rely on advanced biomaterials like zirconia and composite resins. Beyond orthopedics and dentistry, biomaterials are making significant strides in cardiovascular medicine. Stents, heart valves, and vascular grafts are now being produced from bioactive materials that reduce the risk of thrombosis and improve the longevity of the implants. Additionally, tissue engineering and wound care are two growing fields where biomaterials play a pivotal role, with new materials being designed to enhance cellular responses, promote faster healing, and reduce scarring. The demand for bioabsorbable and biocompatible materials is also increasing in drug delivery systems, where these materials help control the release and targeting of therapeutic agents, ensuring higher efficacy and reduced side effects.

What Role Does Technology Play in Advancing Biomaterial Capabilities?

Technological advancements are driving the biomaterials market into new frontiers, particularly through the use of nanotechnology, biotechnology, and smart materials. Nanotechnology has opened the door to nanoscale biomaterials that can interact with biological tissues on a cellular level, enhancing their integration and performance in the body. These nanomaterials are proving to be game-changers in fields like drug delivery, where nanoparticles can be designed to target specific cells or tissues, delivering drugs more efficiently and reducing systemic side effects. Similarly, 3D printing is revolutionizing the way biomaterials are used in healthcare, enabling the production of highly customized implants, prosthetics, and even organ scaffolds that are tailored to individual patient anatomies. Biotechnology is further enhancing the capabilities of biomaterials, with innovations in genetic engineering and tissue scaffolding paving the way for bio-hybrid materials that blend synthetic and biological components. These smart biomaterials can adapt to changes in the body, such as pH, temperature, or chemical signals, making them highly effective in dynamic biological environments. These technological breakthroughs are not only improving the performance of biomaterials but also expanding their applications into areas previously thought impossible.

What Factors Are Driving Growth in the Biomaterials Market?

The growth in the biomaterials market is driven by several factors, including technological advancements, expanding medical applications, and shifting consumer expectations. One of the primary drivers is the increasing prevalence of chronic diseases such as osteoarthritis, cardiovascular diseases, and diabetes, which require advanced biomaterial-based implants, prosthetics, and drug delivery systems. The aging global population is also a significant growth driver, as older individuals are more likely to need orthopedic implants, dental restorations, and cardiovascular devices, all of which depend on cutting-edge biomaterials. Additionally, consumer demand for minimally invasive procedures and faster recovery times is pushing the adoption of biomaterials that promote better integration with the body and enhance healing processes. Technological advancements in areas such as nanotechnology, tissue engineering, and 3D printing are enabling the creation of next-generation biomaterials that offer superior performance and customization. Regulatory support and government funding for research and development in biomaterials, especially for medical and healthcare applications, are further fueling market growth. Moreover, as healthcare systems globally shift towards personalized medicine and regenerative therapies, the demand for bioengineered materials that can be tailored to individual patient needs continues to expand, driving both innovation and market expansion in the biomaterials sector.

SCOPE OF STUDY:

The report analyzes the Biomaterials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Metallic, Polymeric, Ceramic, Natural); Application (Orthopedic, Cardiovascular, Drug Delivery System, Dental, Neurological Disorder, Ophthalmology, Plastic Surgery, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 123 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â